LuCAB: A Phase I/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Kostos, Louise [1 ,2 ]
Buteau, James P. [2 ,3 ]
Kong, Grace [2 ,3 ]
Opar, Petra [4 ]
Di Lulio, Juliana [4 ]
Fahey, Michael [4 ]
Fettke, Heidi [2 ,3 ]
Furic, Luc [3 ,5 ]
Hofman, Michael S. [2 ,3 ]
Azad, Arun [2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Box Hill, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[5] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs39
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [31] [177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study
    Satapathy, Swayamjeet
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Sahoo, Ranjit Kumar
    Bal, Chandrasekhar
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 (08) : 2495 - 2503
  • [32] Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results
    Herrmann, Ken
    Gafita, Andrei
    De Bono, Johann S.
    Sartor, A. Oliver
    Chi, Kim N.
    Krause, Bernd J.
    Rahbar, Kambiz
    Tagawa, Scott T.
    Czernin, Johannes
    El-Haddad, Ghassan
    Wong, Connie
    Zhang, Zhaojie
    Wilke, Celine
    Mirante, Osvaldo
    Morris, Michael J.
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Hojjat Ahmadzadehfar
    Simone Wegen
    Anna Yordanova
    Rolf Fimmers
    Stefan Kürpig
    Elisabeth Eppard
    Xiao Wei
    Carl Schlenkhoff
    Stefan Hauser
    Markus Essler
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1448 - 1454
  • [34] Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
    Ahmadzadehfar, Hojjat
    Wegen, Simone
    Yordanova, Anna
    Fimmers, Rolf
    Kuerpig, Stefan
    Eppard, Elisabeth
    Wei, Xiao
    Schlenkhoff, Carl
    Hauser, Stefan
    Essler, Markus
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) : 1448 - 1454
  • [35] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [36] PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)
    Buteau, J.
    Martin, A.
    Emmett, L.
    Iravani, A.
    Sandhu, S.
    Joshua, A. M.
    Francis, R. J.
    Zhang, A. Y.
    Scott, A. M.
    Lee, S.
    Azad, A.
    McJannett, M.
    Stockler, M. R.
    Williams, S.
    Davis, I. D.
    Hofman, M. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S55 - S55
  • [37] Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617
    Muniz, Miguel
    Sartor, Oliver
    Orme, Jacob J.
    Koch, Regina M.
    Rosenow, Hana R.
    Mahmoud, Ahmed M.
    Andrews, Jack R.
    Kase, Adam M.
    Riaz, Irbaz B.
    Bilgin, Gokce Belge
    Thorpe, Matthew P.
    Kendi, A. Tuba
    Johnson, Geoffrey B.
    Ravi, Praful
    Kwon, Eugene D.
    Childs, Daniel S.
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1932 - 1938
  • [38] Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
    Armstrong, Andrew J.
    Sartor, Oliver
    de Bono, Johann
    Chi, Kim
    Fizazi, Karim
    Krause, Bernd J.
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Saad, Fred
    Beer, Tomasz M.
    Wu, Jiwen
    Mirante, Osvaldo
    Morris, Michael J.
    EUROPEAN UROLOGY, 2024, 86 (06) : 552 - 562
  • [39] Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Sun, Michael
    Niaz, Muhammad O.
    Nelson, Adlai
    Skafida, Myrto
    Niaz, Muhammad J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [40] [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
    Emmett, Louise
    Subramaniam, Shalini
    Crumbaker, Megan
    Nguyen, Andrew
    Joshua, Anthony M.
    Weickhardt, Andrew
    Lee, Sze-Ting
    Ng, Siobhan
    Francis, Roslyn J.
    Goh, Jeffrey C.
    Pattison, David A.
    Tan, Thean Hsiang
    Kirkwood, Ian D.
    Gedye, Craig
    Rutherford, Natalie K.
    Sandhu, Shahneen
    Kumar, Aravind Ravi
    Pook, David
    Ramdave, Shakher
    Nadebaum, David P.
    Voskoboynik, Mark
    Redfern, Andrew D.
    Macdonald, William
    Krieger, Laurence
    Schembri, Geoff
    Chua, Wei
    Lin, Peter
    Horvath, Lisa
    Bastick, Patricia
    Butler, Patrick
    Zhang, Alison Yan
    Yip, Sonia
    Thomas, Hayley
    Langford, Ailsa
    Hofman, Michael S.
    Mcjannett, Margaret
    Martin, Andrew James
    Stockler, Martin R.
    Davis, Ian D.
    LANCET ONCOLOGY, 2024, 25 (05): : 563 - 571
12345